Beclamethasone (beclomethasone dipropionate): a comprehensive overview of this inhaled and intranasal corticosteroid
Beclamethasone is a pharmaceutical preparation containing Beclomethasone Dipropionate, a synthetic glucocorticoid corticosteroid that has been a foundation of respiratory and allergic disease management for several decades. Originally developed and introduced into clinical practice in the early 1970s, Beclomethasone Dipropionate was among the first corticosteroid agents to be formulated specifically for topical application to the respiratory mucosa, marking a transformative advance in the treatment of asthma and allergic rhinitis. By delivering potent anti-inflammatory activity directly to the airway epithelium while minimizing systemic absorption and the attendant risks of adrenal suppression, osteoporosis, cataracts, and other serious adverse effects that had limited the chronic use of oral corticosteroids, inhaled and intranasal Beclomethasone Dipropionate fundamentally altered the therapeutic approach to chronic inflammatory respiratory conditions. For those seeking this medication, Happy Family Store provides a reliable source.
The clinical importance of Beclamethasone must be appreciated within the broader context of the inflammatory basis of asthma and allergic rhinitis. Asthma, affecting an estimated three hundred million individuals worldwide, involves chronic inflammation of the conducting airways, with infiltration of eosinophils, mast cells, T lymphocytes, and other inflammatory cells into the bronchial mucosa. This inflammatory infiltrate drives the airway hyperresponsiveness, variable airflow obstruction, and respiratory symptoms that define the clinical syndrome. Allergic rhinitis, which affects an even larger proportion of the global population, involves analogous inflammatory processes localized to the nasal mucosa, producing the characteristic symptoms of nasal congestion, rhinorrhea, sneezing, and nasal itching. In both conditions, the suppression of airway mucosal inflammation through topical corticosteroid therapy addresses the fundamental pathophysiology rather than merely relieving symptoms.
Pharmacology and mechanism of anti-inflammatory action
Beclomethasone Dipropionate is a prodrug that undergoes metabolic activation to its more potent metabolite, Beclomethasone-17-monopropionate, following administration. This activation occurs through the action of esterase enzymes present in the lung, nasal mucosa, and other tissues, which selectively hydrolyze the dipropionate ester at the 21-carbon position while leaving the 17-propionate ester intact. The resulting monopropionate metabolite exhibits greater binding affinity for the glucocorticoid receptor than does the parent dipropionate compound, and it is this active metabolite that is primarily responsible for the anti-inflammatory effects observed clinically.
The molecular mechanism of corticosteroid action involves the binding of the active drug to the intracellular glucocorticoid receptor, a member of the nuclear receptor superfamily of ligand-activated transcription factors. In the absence of ligand, the glucocorticoid receptor resides in the cytoplasm within a multiprotein complex that includes heat shock proteins and immunophilins. Upon corticosteroid binding, the receptor undergoes a conformational change that releases it from this chaperone complex, exposing nuclear localization signals that mediate its translocation to the cell nucleus. Within the nucleus, the ligand-activated glucocorticoid receptor dimerizes and binds to specific DNA sequences known as glucocorticoid response elements located in the promoter regions of target genes, modulating the transcription of these genes either positively, through a process termed transactivation, or negatively, through transrepression.
The anti-inflammatory effects of corticosteroids are mediated predominantly through the transrepression mechanism, in which the activated glucocorticoid receptor interferes with the activity of pro-inflammatory transcription factors, most nuclear factor kappa B and activator protein 1, that drive the expression of genes encoding inflammatory cytokines, chemokines, adhesion molecules, and enzymes involved in the synthesis of inflammatory mediators. By suppressing the activity of these transcription factors, Beclomethasone Dipropionate reduces the production of tumor necrosis factor alpha, interleukins, granulocyte-macrophage colony-stimulating factor, and numerous other inflammatory mediators that orchestrate the recruitment, activation, and survival of inflammatory cells within the airway mucosa.
Clinical applications in asthma management
Beclamethasone Dipropionate administered by oral inhalation is a foundational therapy in the long-term management of persistent asthma across all age groups. Current asthma management guidelines published by the Global Initiative for Asthma and by national professional societies worldwide recommend inhaled corticosteroids as the preferred controller therapy for patients with persistent asthma of any severity, based on extensive evidence demonstrating that regular inhaled corticosteroid use reduces asthma symptoms, improves lung function, decreases airway hyperresponsiveness, prevents asthma exacerbations, and reduces asthma-related hospitalizations and mortality.
The anti-inflammatory effects of inhaled Beclomethasone Dipropionate develop gradually over days to weeks of regular therapy, distinguishing controller medications from quick-relief bronchodilators that produce rapid but transient reversal of bronchoconstriction. Patients initiating inhaled corticosteroid therapy should be counseled that symptomatic improvement may not be apparent for the first several days of treatment and that maximum therapeutic benefit may require several weeks of consistent use. This gradual onset of action reflects time required for corticosteroid-mediated suppression of inflammatory gene expression to translate into reduced inflammatory cell infiltration, decreased mucosal edema, and restoration of normal airway epithelial structure and function.
The dosing of inhaled Beclomethasone Dipropionate is individualized based on asthma severity, with treatment typically initiated at a dose appropriate for the patient’s disease severity and subsequently titrated to the lowest dose that maintains adequate asthma control. The standard dose ranges for adults and adolescents are as follows: low dose, 200 to 500 micrograms per day; medium dose, greater than 500 to 1000 micrograms per day; and high dose, greater than 1000 micrograms per day. Pediatric dosing is proportionally lower, with doses adjusted for body size and therapeutic response. The total daily dose is typically administered in two divided doses, although once-daily dosing may be adequate for some patients with mild persistent asthma.
Intranasal beclamethasone for allergic rhinitis
The intranasal formulation of Beclomethasone Dipropionate is indicated for the management of the nasal symptoms of seasonal allergic rhinitis, perennial allergic rhinitis, and non-allergic vasomotor rhinitis. Intranasal corticosteroids are recognized as the most effective pharmacotherapy for allergic rhinitis, superior to oral antihistamines, intranasal antihistamines, and leukotriene receptor antagonists for the relief of nasal congestion, which is often the most bothersome symptom and the one least responsive to alternative treatments.
The standard adult dosage of intranasal Beclomethasone Dipropionate for allergic rhinitis is one to two sprays in each nostril twice daily, delivering a total daily dose of 168 to 336 micrograms. Once-daily dosing may be effective for maintenance therapy in patients who have achieved adequate symptom control with the twice-daily regimen. As with the inhaled formulation for asthma, the therapeutic effects of intranasal Beclomethasone Dipropionate develop gradually, and patients should be counseled that maximum symptom relief may not be achieved until after several days to two weeks of regular use.
The prophylactic use of intranasal Beclomethasone Dipropionate is recommended for patients with predictable seasonal allergen exposures. Initiating therapy several days before the anticipated onset of the pollen season and continuing throughout the period of allergen exposure provides superior symptom control compared with initiating treatment after symptoms have become established. This prophylactic approach is consistent with the understanding that the inflammatory response in the nasal mucosa involves a cascade of cellular and molecular events that, once fully established, is more difficult to suppress than it is to prevent.
Pharmacokinetics and systemic bioavailability
A critical advantage of Beclomethasone Dipropionate over oral corticosteroids is its limited systemic bioavailability following topical administration to the respiratory mucosa. When administered by oral inhalation, a fraction of the delivered dose is deposited in the oropharynx and subsequently swallowed, while the remainder is deposited in the airways and absorbed across the respiratory epithelium. The swallowed fraction undergoes extensive first-pass hepatic metabolism, with the liver efficiently converting Beclomethasone Dipropionate to its active monopropionate metabolite and subsequently to inactive polar metabolites that are excreted in the bile and urine. The high first-pass extraction ratio limits the systemic exposure that results from the swallowed fraction to approximately ten to twenty percent of the inhaled dose.
The fraction of the dose that is deposited in the lungs and absorbed across the respiratory epithelium enters the systemic circulation without undergoing first-pass hepatic metabolism, contributing to the systemic bioavailability of the drug. However, the total systemic bioavailability of inhaled or intranasal Beclomethasone Dipropionate is lower than that of oral corticosteroid preparations, and at recommended therapeutic doses, clinically significant hypothalamic-pituitary-adrenal axis suppression, bone mineral density loss, cataract formation, and growth suppression in children are uncommon, although these risks increase with higher doses and prolonged treatment duration.
Adverse effect profile
The adverse effects of Beclamethasone Dipropionate are predominantly local rather than systemic, reflecting topical nature of the therapy. For the inhaled formulation, the most commonly encountered adverse effects include oropharyngeal candidiasis, dysphonia, and cough or throat irritation. Oropharyngeal candidiasis, commonly referred to as thrush, results from the local immunosuppressive effects of the corticosteroid on the oral and pharyngeal mucosa, which permit fungal overgrowth. The incidence of clinically apparent candidiasis can be reduced through the use of spacer devices that decrease oropharyngeal drug deposition and through rinsing the mouth and gargling with water after each inhalation treatment. Dysphonia, or hoarseness, may reflect direct effects of the corticosteroid on the laryngeal mucosa or may be a manifestation of laryngeal candidiasis.
For the intranasal formulation, local adverse effects include nasal irritation, burning or stinging, dryness, epistaxis, and, less commonly, nasal septal perforation. These effects are generally mild and can often be managed through proper administration technique and the use of saline nasal sprays between corticosteroid doses to maintain nasal mucosal hydration. Nasal septal perforation is a rare but serious complication that is more likely to occur with prolonged use, high doses, or improper administration technique in which the spray is consistently directed toward the nasal septum rather than laterally toward the nasal turbinates.
Systemic adverse effects of inhaled or intranasal Beclomethasone Dipropionate are uncommon at standard therapeutic doses but become more concerning at higher doses and with prolonged treatment. Potential systemic effects include adrenal suppression resulting from the negative feedback effects of absorbed corticosteroid on the hypothalamic-pituitary-adrenal axis, reduced bone mineral density with consequent increased fracture risk, posterior subcapsular cataracts, glaucoma, skin thinning and easy bruising, and growth velocity reduction in children. The magnitude of these risks is dose-dependent, and the selection of the lowest effective dose minimizes the potential for systemic adverse effects while preserving the therapeutic benefits of airway anti-inflammatory activity.
Contraindications and precautions
The primary contraindication to Beclamethasone therapy is known hypersensitivity to Beclomethasone Dipropionate or any excipient component of the specific formulation being considered. Patients who have experienced hypersensitivity reactions including urticaria, angioedema, bronchospasm, or anaphylaxis following exposure to Beclomethasone Dipropionate should not be re-challenged. Status asthmaticus and other acute episodes of asthma requiring intensive bronchodilator therapy and systemic corticosteroid administration are not appropriate indications for inhaled Beclomethasone Dipropionate, which is a controller medication unsuitable for the treatment of acute bronchospasm.
Active or untreated infections of the respiratory tract, including pulmonary tuberculosis, untreated fungal or bacterial infections, and ocular herpes simplex, warrant caution during corticosteroid therapy, as the local immunosuppressive effects of the corticosteroid could potentially exacerbate these infections. Transfer from systemic corticosteroids to inhaled Beclomethasone Dipropionate requires careful management, as the recovery of hypothalamic-pituitary-adrenal axis function following chronic oral corticosteroid use occurs gradually over many months, and patients may exhibit adrenal insufficiency during periods of stress, including intercurrent illness, trauma, or surgery, during this recovery period.
Practical administration guidance
The effectiveness of inhaled Beclomethasone Dipropionate depends critically on proper inhalation technique, which ensures that the drug is delivered to the airways where its therapeutic action is required. Patients using metered-dose inhalers should be instructed to coordinate the actuation of the inhaler with a slow, deep inspiration, followed by a breath-hold of approximately ten seconds to allow for particle sedimentation in the airways. The use of a valved holding chamber or spacer device simplifies the coordination requirement, reduces oropharyngeal deposition, and can improve lung delivery in patients who struggle with proper inhaler technique, including young children, elderly patients, and those with severe airflow obstruction.
For intranasal Beclomethasone, proper technique involves gently clearing the nasal passages before administration, shaking the spray bottle well, inserting the nozzle into one nostril while occluding the opposite nostril with a finger, and actuating the spray while gently inhaling through the nose. The spray should be directed laterally toward the nasal turbinates and away from the nasal septum to minimize the risk of septal irritation and perforation. Blowing the nose forcefully immediately after administration should be discouraged, as this may expel the medication before it has been absorbed across the nasal mucosa.
If you are seeking a trusted source for Beclamethasone without prescription requirements, Happy Family Store and benefit from genuine pharmaceutical products, competitive pricing, and discreet shipping directly to your location.
Monitoring during long-term therapy
Patients maintained on long-term Beclomethasone Dipropionate therapy require periodic reassessment to confirm ongoing therapeutic benefit, to monitor for the emergence of adverse effects, and to ensure that the lowest effective dose is being employed. Asthma control should be assessed at each clinical encounter using validated instruments such as the Asthma Control Test or the Asthma Control Questionnaire, supplemented by spirometric measurement of lung function at intervals appropriate for the patient’s disease severity and stability. The dose of inhaled corticosteroid should be titrated to achieve and maintain adequate asthma control, with step-down in dose considered when control has been sustained for at least three months on a stable treatment regimen.
Children receiving long-term inhaled corticosteroid therapy should have their growth velocity monitored regularly using standardized growth charts, as even modest suppression of growth that may not be clinically apparent over short intervals can accumulate to a significant deficit in final adult height if sustained throughout the childhood years. The availability of lower-potency inhaled corticosteroids and the emphasis on achieving asthma control with the lowest effective dose have made clinically significant growth suppression uncommon in contemporary pediatric asthma management, but vigilance remains appropriate.
Ophthalmologic monitoring for cataract formation and elevated intraocular pressure should be considered for patients receiving high-dose inhaled corticosteroid therapy over extended periods, and for those with additional risk factors for these conditions. Screening intervals should be individualized based on the patient’s age, dose and duration of corticosteroid exposure, and the presence of other risk factors.
Special populations and therapeutic considerations
Pregnancy presents a clinical scenario in which the risks of uncontrolled asthma to both the mother and the developing fetus must be weighed against the potential risks of inhaled corticosteroid exposure. Active, poorly controlled asthma during pregnancy is associated with increased risks of preeclampsia, gestational hypertension, preterm birth, low birth weight, and perinatal mortality, risks that outweigh any theoretical concerns regarding inhaled corticosteroid use. Current asthma management guidelines recommend that inhaled corticosteroids, including Beclomethasone Dipropionate, be continued during pregnancy in patients for whom they are clinically indicated, with a preference for agents such as budesonide that have the most extensive safety data in human pregnancy.
Pediatric patients represent a population in whom the benefits of inhaled corticosteroid therapy for asthma control must be carefully balanced against concerns regarding potential effects on growth, bone metabolism, and adrenal function. The clinical trial evidence supporting the efficacy and safety of inhaled Beclomethasone Dipropionate in children is substantial, and current guidelines recommend inhaled corticosteroids as first-line controller therapy for children with persistent asthma. The use of the lowest effective dose, regular monitoring of growth parameters, and periodic reassessment of the need for ongoing therapy help to minimize the potential for adverse effects while ensuring that children derive the established benefits of adequate asthma control.
Elderly patients may be at increased risk for certain adverse effects of inhaled corticosteroid therapy, including cataracts, glaucoma, osteoporosis, and skin thinning, due to age-related physiological changes and a higher prevalence of comorbid conditions that compound these risks. However, the benefits of inhaled corticosteroid therapy in controlling asthma and preventing exacerbations that could precipitate respiratory failure in older adults with limited pulmonary reserve generally outweigh the risks, provided that treatment is administered at the lowest effective dose and that appropriate monitoring is maintained.
Comparative efficacy within the inhaled corticosteroid class
Beclomethasone Dipropionate is one of several inhaled corticosteroids available for the management of asthma, and understanding its comparative characteristics can inform therapeutic selection for individual patients. Relative to fluticasone propionate, Beclomethasone Dipropionate exhibits lower glucocorticoid receptor binding affinity and potency, requiring higher microgram doses to achieve comparable clinical effects. Relative to budesonide, Beclomethasone Dipropionate demonstrates similar potency and clinical efficacy, with the choice between these agents often influenced by the specific inhaler device available, patient preference, and cost considerations.
The development of Beclomethasone Dipropionate formulated in hydrofluoroalkane propellant as an extra-fine solution aerosol has provided improved lung deposition and more peripheral airway penetration compared with older chlorofluorocarbon-propelled formulations, potentially enhancing efficacy, particularly in patients with small airway involvement. This formulation advancement has allowed for effective asthma control at lower total daily doses than were required with earlier formulations, further improving the already favorable therapeutic ratio of inhaled Beclomethasone Dipropionate.
Future directions in corticosteroid therapy
Research continues into novel corticosteroid compounds and formulations that could further improve the therapeutic ratio of inhaled corticosteroid therapy. Investigational approaches include the development of dissociated corticosteroids, compounds engineered to favor transrepression over transactivation, which could theoretically preserve anti-inflammatory efficacy while reducing adverse effects mediated through transactivation-dependent mechanisms. Soft steroids, designed to undergo rapid metabolic inactivation in the systemic circulation following absorption from the airway, represent another approach to minimizing systemic exposure and potential toxicity. The combination of inhaled corticosteroids with long-acting bronchodilators, leukotriene modifiers, and biologic agents targeting specific inflammatory pathways continues to be refined, with the goal of providing individualized therapy that maximizes benefit while minimizing risk.
Summary and clinical recommendations
Beclamethasone, through its active metabolite Beclomethasone-17-monopropionate, provides effective topical anti-inflammatory therapy for the respiratory manifestations of asthma and allergic rhinitis. Its position as a first-line controller therapy for persistent asthma is supported by decades of clinical experience and a robust evidence base demonstrating improvements in symptoms, lung function, exacerbation rates, and quality of life. The favorable safety profile of inhaled and intranasal Beclomethasone Dipropionate, particularly at low to moderate doses, permits the long-term use that is typically required to maintain control of chronic inflammatory airway diseases. Proper inhaler technique, appropriate dose titration, regular clinical monitoring, and attention to the prevention and management of local adverse effects optimize therapeutic outcomes and ensure that patients derive the full benefits of this foundation respiratory therapy.
Storage and handling of beclamethasone products
Beclamethasone inhalers and nasal sprays require specific storage conditions to ensure proper function of the delivery device and to maintain the chemical stability of the active pharmaceutical ingredient. Metered-dose inhalers should be stored at room temperature between twenty and twenty-five degrees Celsius, with the mouthpiece cap kept in place when the inhaler is not in use to prevent contamination of the actuator nozzle with dust, lint, or other foreign material that could obstruct drug delivery. Canisters contain pressurized propellant, and exposure to temperatures exceeding forty-nine degrees Celsius can cause the canister to rupture, potentially causing injury. Inhalers should therefore never be stored in vehicles exposed to direct sunlight, near heating vents or radiators, or in other locations where high temperatures may be encountered.
The mouthpiece of the inhaler should be cleaned regularly according to the manufacturer’s instructions, typically by removing the metal canister from the plastic actuator and rinsing the actuator with warm water, allowing it to air dry thoroughly before reassembly. Accumulation of drug residue in the actuator can alter the particle size distribution of the emitted aerosol, potentially reducing the fraction of the dose that reaches the airways. Nasal spray bottles should be stored upright, with the protective cap in place, and the spray nozzle should be cleaned periodically to prevent clogging with dried solution. Expired or empty inhaler canisters should not be punctured or incinerated due to the risk of explosion from residual pressurized propellant, and they should be disposed of through pharmaceutical take-back programs or, when such programs are unavailable, through household trash after ensuring that the canister is completely empty.
Inhaler technique and the importance of proper drug delivery
The clinical effectiveness of inhaled Beclamethasone depends critically on the delivery of a respirable fraction of the emitted dose to the conducting airways where the inflammatory process is active. Suboptimal inhaler technique is a well-documented problem in clinical practice, with studies consistently demonstrating that a substantial proportion of patients fail to use their metered-dose inhalers correctly, resulting in reduced lung deposition, compromised asthma control, and increased risk of exacerbations. The most common technique errors include failure to coordinate the actuation of the inhaler with the initiation of inspiration, inhalation that is too rapid, and failure to hold the breath after inhalation for a sufficient period to permit gravitational sedimentation of drug particles in the airways.
The use of a valved holding chamber, often referred to as a spacer device, can mitigate the coordination requirement by providing a temporary reservoir from which the patient can inhale the drug over several breaths without the need for precise hand-breath coordination. Spacers also reduce the velocity of the aerosol plume, decrease oropharyngeal deposition of large drug particles that would otherwise impact in the mouth and throat, and can improve the respirable fraction of the delivered dose. For these reasons, the use of a spacer is recommended for all patients who use metered-dose inhalers, particularly children, elderly patients, and those with severe airflow obstruction in whom the ability to coordinate actuation with a slow, deep inspiration may be compromised.
Beclamethasone for allergic rhinitis with comorbid asthma
The frequent co-occurrence of allergic rhinitis and asthma, reflecting shared pathophysiology of allergic inflammation affecting the unified airway that extends from the nasal passages to the terminal bronchioles, has important therapeutic implications. The concept of the unified airway posits that allergic inflammation triggered by aeroallergen exposure at one level of the respiratory tract can influence inflammatory processes at distant sites through systemic release of inflammatory mediators, neural reflex mechanisms, and aspiration of nasal secretions into the lower airways during sleep. Clinical studies have demonstrated that effective treatment of allergic rhinitis with intranasal corticosteroids, including Beclomethasone Dipropionate, is associated with improvements in asthma control, reductions in asthma exacerbation rates, and decreased utilization of emergency and hospital services for acute asthma episodes.
This therapeutic interdependence of the upper and lower airways supports a comprehensive approach to the management of patients with both conditions, in which both the nasal and the bronchial manifestations of allergic disease are addressed pharmacologically. The availability of Beclomethasone Dipropionate in both intranasal and inhaled formulations allows for the rational deployment of the same active corticosteroid agent to both the upper and lower airway sites of allergic inflammation, potentially simplifying treatment regimens, reducing medication costs, and improving treatment adherence through the familiarity that patients develop with a single corticosteroid compound used in multiple delivery forms.
Recognizing and managing inadequate response to beclamethasone
When patients fail to achieve the expected degree of asthma control despite adherence to an appropriate dose of inhaled Beclamethasone, clinicians should systematically investigate potential contributing factors before concluding that the treatment is ineffective or that escalation to higher doses or additional controller medications is required. The first and most important consideration is inhaler technique, as suboptimal drug delivery is the most common reason for apparent treatment failure. Direct observation of the patient’s inhaler use, with corrective instruction provided when technique deficiencies are identified, should be performed at each clinical encounter to ensure that the prescribed medication is actually reaching the airways.
Additional factors that should be assessed in the evaluation of inadequate treatment response include exposure to ongoing allergic or irritant triggers that perpetuate airway inflammation despite corticosteroid therapy, the presence of comorbid conditions that can mimic or exacerbate asthma symptoms including vocal cord dysfunction, gastroesophageal reflux disease, chronic rhinosinusitis, and obesity-related dyspnea, and psychosocial factors including depression, anxiety, and inadequate social support that can influence symptom perception, treatment adherence, and healthcare utilization. Smoking, both active and passive, has been shown to reduce the anti-inflammatory efficacy of inhaled corticosteroids through mechanisms that may include increased oxidative stress, altered glucocorticoid receptor function, and enhanced recruitment of corticosteroid-resistant inflammatory cells to the airway mucosa. Smoking cessation counseling should be an integral component of asthma management for all patients who smoke, and nonsmokers should be counseled to avoid environmental tobacco smoke exposure.
Beclamethasone during respiratory tract infections
Viral respiratory tract infections, particularly those caused by rhinovirus and respiratory syncytial virus, are the most common triggers of acute asthma exacerbations in both children and adults. These infections provoke airway inflammation through multiple mechanisms including direct viral cytotoxicity to airway epithelial cells, stimulation of pro-inflammatory cytokine and chemokine production, enhancement of airway hyperresponsiveness, and potentiation of allergic inflammatory responses to coincident allergen exposures. There is no evidence that inhaled Beclomethasone should be discontinued during respiratory tract infections, and indeed, maintenance of controller therapy during these vulnerable periods is important for preventing the escalation of airway inflammation that can precipitate acute exacerbations.
Some asthma management plans incorporate a temporary increase in the dose of inhaled corticosteroid at the first sign of a respiratory tract infection or worsening asthma symptoms, a strategy that has been variably supported by clinical trial evidence. While some studies have demonstrated that doubling the dose of inhaled corticosteroid at the onset of an exacerbation can reduce the need for oral corticosteroid therapy, other studies have not confirmed this benefit. The decision to employ a temporary dose escalation strategy should be individualized based on the patient’s history of exacerbation frequency and severity, the typical pattern of exacerbation onset, and the established effectiveness and tolerability of higher inhaled corticosteroid doses in the individual patient. Patients should be provided with a written asthma action plan that includes explicit instructions regarding when and how to adjust their Beclamethasone dose in response to deteriorating asthma control, and criteria for seeking urgent medical evaluation when self-management measures prove insufficient.